<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03657446</url>
  </required_header>
  <id_info>
    <org_study_id>ID-054-107</org_study_id>
    <secondary_id>2018-002118-12</secondary_id>
    <nct_id>NCT03657446</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Subjects to Investigate Whether Administration of Clazosentan Can Affect Normal Heart Function</brief_title>
  <official_title>Randomized, Double-blind (for Clazosentan), Placebo- and Moxifloxacincontrolled, 3-way Cross-over Phase 1 Study to Assess the Effect of Two Intravenous Doses of Clazosentan on the QTc Interval Duration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate whether administration of clazosentan can affect normal heart
      function in healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">October 26, 2018</completion_date>
  <primary_completion_date type="Actual">October 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>3-way cross-over Phase 1 study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Placebo-corrected change-from-baseline QTcF (ΔΔQTcF) with its upper limit of the two-sided 95% confidence interval (CI)</measure>
    <time_frame>From 1 hour pre-dose to 24 hour after the end of infusion</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacinn</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period A: clazosentan Period B: placebo Period C: placebo + moxifloxacin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clazosentan</intervention_name>
    <description>Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo infusion</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Film-coated tablet containing 400 mg moxifloxacin</description>
    <arm_group_label>Treatment sequence ABC</arm_group_label>
    <arm_group_label>Treatment sequence ACB</arm_group_label>
    <arm_group_label>Treatment sequence BAC</arm_group_label>
    <arm_group_label>Treatment sequence BCA</arm_group_label>
    <arm_group_label>Treatment sequence CAB</arm_group_label>
    <arm_group_label>Treatment sequence CBA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General criteria

          -  Signed informed consent prior to any study-mandated procedure

          -  Body mass index of 18.0-30.0 kg/m2 (inclusive) at Screening

          -  Systolic blood pressure 100−145 mmHg, diastolic blood pressure 50−90 mmHg, and pulse
             rate 45−90 bpm (inclusive), measured on the same arm, after 5 min in the supine
             position at Screening and on Day -1 of the first Period

          -  12-lead ECG: QT interval corrected using Fridericia's formula (QTcF) &lt;450 ms for male
             subjects and &lt; 470 ms for female subjects, QRS interval &lt; 110 ms, PR interval ≤ 200
             ms, and heart rate (HR) ≤ 90 bpm without clinically relevant abnormalities using a
             12-lead ECG measured after 5 min in the supine position at Screening and on Day -1 of
             the first Period

        Study-specific criteria

          -  Women of non-childbearing potential

          -  Male subjects must accept to use a condom and not to procreate for the duration of the
             study and for 3 months thereafter

        Exclusion Criteria:

        General criteria

          -  Previous exposure to clazosentan or to moxifloxacin within 3 months prior to Screening

          -  Known hypersensitivity to any of clazosentan excipients or to moxifloxacin or any of
             its excipients

          -  Any contraindication to moxifloxacin treatment

          -  Acute, ongoing, recurrent, or chronic systemic disease able to interfere with the
             evaluation of the study

          -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal
             reactions if considered clinically significant by the investigator

          -  Veins unsuitable for i.v. puncture on either arm (e.g., veins that are difficult to
             locate, access, or puncture, veins with a tendency to rupture during or after
             puncture)

          -  Participation in a clinical study involving study treatment administration within 3
             months prior to Screening or in more than 4 clinical studies within 1 year prior to
             Screening

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol

        Study-specific criteria

        • History or presence of rhythm disorders (e.g., sinoatrial heart block, sick-sinus
        syndrome, second- or third-degree atrioventricular block, long QT syndrome, symptomatic
        bradycardia, atrial flutter, or atrial fibrillation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS Netherlands B.V.</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <last_update_submitted>November 19, 2018</last_update_submitted>
  <last_update_submitted_qc>November 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

